XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

類似資料

• XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
  著者:: Deng, Manman, 等
  出版事項: (2020)
• A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL
  著者:: Xu-Monette, Zijun Y., 等
  出版事項: (2020)
• Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
  著者:: Nakayama, Robert, 等
  出版事項: (2016)
• Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
  著者:: Xu-Monette, Zijun Y., 等
  出版事項: (2019)
• XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
  著者:: Crochiere, Marsha L., 等
  出版事項: (2017)